[go: up one dir, main page]

AR046833A1 - Anticuerpos anti-interleuquina-10 - Google Patents

Anticuerpos anti-interleuquina-10

Info

Publication number
AR046833A1
AR046833A1 ARP040104114A ARP040104114A AR046833A1 AR 046833 A1 AR046833 A1 AR 046833A1 AR P040104114 A ARP040104114 A AR P040104114A AR P040104114 A ARP040104114 A AR P040104114A AR 046833 A1 AR046833 A1 AR 046833A1
Authority
AR
Argentina
Prior art keywords
seq
amino acid
acid sequence
entirety
structure region
Prior art date
Application number
ARP040104114A
Other languages
English (en)
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of AR046833A1 publication Critical patent/AR046833A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
    • C07K16/464—Igs containing CDR-residues from one specie grafted between FR-residues from another
    • C07K16/465—Igs containing CDR-residues from one specie grafted between FR-residues from another with additional modified FR-residues
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/54—Interleukins [IL]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • G01N33/6857—Antibody fragments

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Virology (AREA)
  • Diabetes (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Pain & Pain Management (AREA)
  • AIDS & HIV (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Transplantation (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)

Abstract

Los métodos y composiciones proporcionados se refieren, en general, a anticuerpos específicos contra IL-10 y sus usos. Más específicamente, las composiciones de anticuerpos específicos contra IL-10 humanizados y métodos para utilizar ese tipo de anticuerpos en la modulación de la actividad biológica de IL-10, particularmente en trastornos autoinmunes e inmunopatología mediada por un patógeno. Además se proporcionan ácidos nucleicos que codifican dichos polipéptidos así como vectores, células huésped y métodos para producirlas. Reivindicación 1: Una molécula de anticuerpo recombinante humanizado que une IL-10 o su fragmento, que comprende: por lo menos una región variable de cadena liviana de anticuerpo, o su fragmento de unión, que comprende un polipéptido que tiene por lo menos una secuencia de aminoácidos seleccionada del grupo formado por SEC ID NO: 1 en CDR1, SEC ID NO: 2 en CDR2, SEC ID NO: 3 en CDR3; y una región de estructura, en donde la secuencia de aminoácidos de la región de estructura es de su totalidad o sustancialmente en su totalidad una secuencia de aminoácidos de inmunoglobina humana; y por lo menos una región variable de cadena pesada de anticuerpo, o su fragmento de unión, que comprende un polipéptido que tiene por lo menos una secuencia de aminoácidos seleccionada del grupo formado por SEC ID NO: 6 en CDR1, SEC ID NO: 7 en CDR2, y SEC ID NO: 8 en CDR3; y una región de estructura, en donde la secuencia de aminoácidos de la región de estructura es en su totalidad o sustancialmente en su totalidad una secuencia de aminoácidos de inmunoglobina humana.
ARP040104114A 2003-11-10 2004-11-08 Anticuerpos anti-interleuquina-10 AR046833A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US51899903P 2003-11-10 2003-11-10

Publications (1)

Publication Number Publication Date
AR046833A1 true AR046833A1 (es) 2005-12-28

Family

ID=34590335

Family Applications (3)

Application Number Title Priority Date Filing Date
ARP040104114A AR046833A1 (es) 2003-11-10 2004-11-08 Anticuerpos anti-interleuquina-10
ARP090104951A AR074780A2 (es) 2003-11-10 2009-12-17 Metodo para humanizar anticuerpos contra interleuquina 10 (il-10)
ARP090104950A AR074779A2 (es) 2003-11-10 2009-12-17 Anticuerpos contra interleuquina -10

Family Applications After (2)

Application Number Title Priority Date Filing Date
ARP090104951A AR074780A2 (es) 2003-11-10 2009-12-17 Metodo para humanizar anticuerpos contra interleuquina 10 (il-10)
ARP090104950A AR074779A2 (es) 2003-11-10 2009-12-17 Anticuerpos contra interleuquina -10

Country Status (25)

Country Link
US (5) US20050101770A1 (es)
EP (4) EP2292661A3 (es)
JP (4) JP4762148B2 (es)
KR (3) KR20120025618A (es)
CN (2) CN102010471A (es)
AR (3) AR046833A1 (es)
AT (1) ATE440867T1 (es)
AU (2) AU2004290044B2 (es)
CA (2) CA2545255C (es)
CY (1) CY1110557T1 (es)
DE (1) DE602004022855D1 (es)
DK (1) DK1694705T3 (es)
ES (1) ES2329907T3 (es)
HR (1) HRP20090517T1 (es)
IL (3) IL175523A (es)
NO (1) NO20062672L (es)
NZ (1) NZ546632A (es)
PE (3) PE20050925A1 (es)
PL (1) PL1694705T3 (es)
PT (1) PT1694705E (es)
RS (1) RS51180B (es)
SG (1) SG155205A1 (es)
SI (1) SI1694705T1 (es)
WO (2) WO2005047324A2 (es)
ZA (1) ZA200603681B (es)

Families Citing this family (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2429769C (en) * 2000-12-07 2016-04-26 Board Of Regents, The University Of Texas System Methods of treatment involving human mda-7
WO2002057283A1 (en) * 2001-01-19 2002-07-25 Baylor College Of Medecine Methods and compositions in breast cancer diagnosis and therapeutics
US20040009939A1 (en) * 2002-03-05 2004-01-15 Board Of Regent, The University Of Texas System Methods of enhancing immune induction involving MDA-7
CA2548220A1 (en) * 2003-12-01 2005-09-09 Introgen Therapeutics, Inc. Use of mda-7 to inhibit infection by pathogenic organisms
ES2301972T3 (es) * 2004-02-23 2008-07-01 Synthes Gmbh Tornillo para huesos.
US20070281041A1 (en) * 2004-03-02 2007-12-06 Introgen Therapeutics, Inc. Compositions and Methods Involving MDA-7 for the Treatment of Cancer
WO2006086798A2 (en) * 2005-02-08 2006-08-17 Board Of Regents, The University Of Texas System Compositions and methods involving mda-7 for the treatment of cancer
US20110104109A1 (en) * 2005-07-13 2011-05-05 Frank Bennett Tetracyclic indole derivatives and their use for treating or preventing viral infections
JP5350793B2 (ja) 2005-08-31 2013-11-27 メルク・シャープ・アンド・ドーム・コーポレーション 改変抗ｉｌ−２３抗体
WO2007092944A2 (en) * 2006-02-08 2007-08-16 Introgen Therapeutics, Inc. Compositions and methods involving gene therapy and proteasome modulation
PT2066695E (pt) * 2006-09-05 2013-05-23 Lilly Co Eli Anticorpos anti-miostatina
PH12013500355A1 (en) 2006-12-14 2021-08-09 Schering Corp Engineered anti-tslp antibody
CN101679519A (zh) 2006-12-22 2010-03-24 先灵公司 Cd200r的抗体
WO2008082484A1 (en) 2006-12-22 2008-07-10 Schering Corporation 4,5-ring annulated indole derivatives for treating or preventing of hcv and related viral infections
CN101611025A (zh) 2006-12-22 2009-12-23 先灵公司 5,6-环化的吲哚衍生物及其使用方法
WO2008082488A1 (en) * 2006-12-22 2008-07-10 Schering Corporation 4, 5-ring annulated indole derivatives for treating or preventing of hcv and related viral infections
DK2059534T3 (da) 2007-02-23 2012-08-06 Merck Sharp & Dohme Gensplejsede anti-il-23p19-antistoffer
EP2064242A1 (en) 2007-02-23 2009-06-03 Schering Corporation Engineered anti-il-23p19 antibodies
JP5238723B2 (ja) 2007-02-28 2013-07-17 メルク・シャープ・アンド・ドーム・コーポレーション 操作された抗ｉｌ−２３ｒ抗体
BRPI0816116A2 (pt) * 2007-08-29 2015-03-03 Schering Corp Derivados de indol 2,3-substituídos para o tratamento de infecções virais.
AU2008295484B2 (en) * 2007-08-29 2013-09-26 Merck Sharp & Dohme Llc Substituted indole derivatives and methods of use thereof
TW200911807A (en) * 2007-08-29 2009-03-16 Schering Corp 2,3-substituted azaindole derivatives and methods of use thereof
CN102317285A (zh) * 2007-11-16 2012-01-11 先灵公司 3-氨基磺酰基取代的吲哚衍生物及其使用方法
MX2010005356A (es) * 2007-11-16 2010-05-27 Schering Corp Derivados de indol 3-heterociclico sustituidos y metodos de uso de los mismos.
AR072088A1 (es) * 2008-06-13 2010-08-04 Schering Corp Derivados de indol triciclicos y sus metodos de uso
WO2010027488A2 (en) * 2008-09-04 2010-03-11 Vet Therapeutics, Inc. Monoclonal antibodies
MX2011008843A (es) * 2009-02-23 2011-12-14 Glenmark Pharmaceuticals Sa Anticuerpos humanizados que se unen a cd19 y sus usos.
AU2010253791A1 (en) 2009-05-29 2011-11-24 Merck Sharp & Dohme Corp. Antiviral compounds composed of three linked Aryl moieties to treat diseases such as Hepatitis C
AU2010289677B2 (en) 2009-09-03 2014-07-31 Merck Sharp & Dohme Llc Anti-GITR antibodies
CA2782024A1 (en) 2009-11-25 2011-06-03 Schering Corporation Fused tricyclic compounds and derivatives thereof useful for the treatment of viral diseases
KR101802260B1 (ko) * 2009-11-30 2017-11-28 바이오테스트 아게 전신 홍반성 낭창을 치료하기 위한 인간화된 항-ｉｌ-10 항체
US20130156731A1 (en) 2009-12-22 2013-06-20 Kevin X. Chen Fused tricyclic compounds and methods of use thereof for the treatment of viral diseas
US9433621B2 (en) 2010-02-18 2016-09-06 Merck Sharp & Dohme Corp. Substituted pyridine and pyrimidine derivatives and their use in treating viral infections
ES2558554T3 (es) 2010-03-09 2016-02-05 Merck Sharp & Dohme Corp. Compuestos de sililo tricíclicos condensados y métodos de uso de los mismos para el tratamiento de enfermedades víricas
AU2011268110B2 (en) 2010-06-19 2016-05-19 Memorial Sloan-Kettering Cancer Center Anti-GD2 antibodies
AU2011286276A1 (en) 2010-07-26 2013-01-24 Merck Sharp & Dohme Corp. Substituted biphenylene compounds and methods of use thereof for the treatment of viral diseases
WO2012050848A1 (en) 2010-09-29 2012-04-19 Schering Corporation Fused tetracycle derivatives and methods of use thereof for the treatment of viral diseases
EP3211009A1 (en) 2010-11-23 2017-08-30 Glaxo Group Limited Antigen binding proteins to oncostatin m (osm)
ES2865068T3 (es) 2011-01-14 2021-10-14 Univ California Anticuerpos terapéuticos contra la proteína ROR-1 y métodos para usarlos
WO2012142085A1 (en) 2011-04-13 2012-10-18 Merck Sharp & Dohme Corp. 2'-substituted nucleoside derivatives and methods of use thereof for the treatment of viral diseases
EP2697242B1 (en) 2011-04-13 2018-10-03 Merck Sharp & Dohme Corp. 2'-azido substituted nucleoside derivatives and methods of use thereof for the treatment of viral diseases
CN102250243B (zh) * 2011-07-01 2013-08-28 华绍炳 抗白细胞介素-15抗体
WO2013033900A1 (en) 2011-09-08 2013-03-14 Merck Sharp & Dohme Corp. Tetracyclic heterocycle compounds and methods of use thereof for the treatment of viral diseases
WO2013039876A1 (en) 2011-09-14 2013-03-21 Merck Sharp & Dohme Corp. Silyl-containing heterocyclic compounds and methods of use thereof for the treatment of viral diseases
US9512405B2 (en) 2011-12-14 2016-12-06 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Non-enzymatic method for isolating human adipose-derived stromal stem cells
UA117466C2 (uk) 2012-12-13 2018-08-10 Мерк Шарп Енд Доме Корп. СТАБІЛЬНИЙ СКЛАД У ВИГЛЯДІ РОЗЧИНУ АНТИТІЛА ДО IL-23p19
JP6482525B2 (ja) 2013-03-15 2019-03-13 メモリアル スローン ケタリング キャンサー センター 高親和性抗ｇｄ２抗体
AR097306A1 (es) 2013-08-20 2016-03-02 Merck Sharp & Dohme Modulación de la inmunidad tumoral
CN105277638A (zh) * 2014-07-22 2016-01-27 沈鹤霄 一种单克隆抗体IgG质谱测序方法
JO3663B1 (ar) 2014-08-19 2020-08-27 Merck Sharp & Dohme الأجسام المضادة لمضاد lag3 وأجزاء ربط الأنتيجين
BR112017025562A2 (pt) * 2015-05-29 2018-08-07 Merck Sharp & Dohme Corp. métodos para tratar câncer em um indivíduo e para tratar um indivíduo humano diagnosticado com câncer
AU2016271023A1 (en) * 2015-05-29 2017-11-30 Dynavax Technologies Corporation Combination of an anti-IL-10 antibody and a CPG-C type oligonucleotide for treating cancer
KR102317574B1 (ko) 2015-11-18 2021-10-26 머크 샤프 앤드 돔 코포레이션 Pd1 및/또는 lag3 결합제
EP3399989B1 (en) 2015-12-16 2023-08-09 Merck Sharp & Dohme LLC Anti-lag3 antibodies and antigen-binding fragments
EP3394099A4 (en) * 2015-12-22 2019-11-27 Merck Sharp & Dohme Corp. Formulations of Manipulated Anti- IL-10 Antibodies
JP7382232B2 (ja) 2017-05-02 2023-11-16 メルク・シャープ・アンド・ドーム・エルエルシー 抗ｌａｇ３抗体の製剤および抗ｌａｇ３抗体と抗ｐｄ－１抗体との共製剤
JOP20190260A1 (ar) 2017-05-02 2019-10-31 Merck Sharp & Dohme صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها
US12023353B2 (en) 2017-10-18 2024-07-02 Chemotherapeutisches Forschungsinstitut Georg-Speyer-Haus Methods and compounds for improved immune cell therapy
EP3768725A4 (en) * 2018-03-20 2021-06-02 Wuxi Biologics Ireland Limited NEW ANTI-TIM-3 ANTIBODIES
KR20210089215A (ko) 2018-11-07 2021-07-15 머크 샤프 앤드 돔 코포레이션 항-lag3 항체 및 항-pd-1 항체의 공동-제제
US20240092886A1 (en) * 2019-10-09 2024-03-21 Rush University Medical Center Modulating interleukin-10 signaling to boost healing in diabetic wounds
KR20230110304A (ko) 2020-11-18 2023-07-21 아스트라제네카 아베 스테로이드 절약
WO2022257106A1 (zh) * 2021-06-11 2022-12-15 江苏丰华生物制药有限公司 一种人源化抗人GPVI单克隆抗体Fab片段及其应用
EP4608450A1 (en) * 2022-10-24 2025-09-03 Merck Sharp & Dohme LLC Human hyaluronidase 1 mutants

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL154598B (nl) 1970-11-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking.
US3817837A (en) 1971-05-14 1974-06-18 Syva Corp Enzyme amplification assay
US3939350A (en) 1974-04-29 1976-02-17 Board Of Trustees Of The Leland Stanford Junior University Fluorescent immunoassay employing total reflection for activation
US3996345A (en) 1974-08-12 1976-12-07 Syva Company Fluorescence quenching with immunological pairs in immunoassays
US4275149A (en) 1978-11-24 1981-06-23 Syva Company Macromolecular environment control in specific receptor assays
US4277437A (en) 1978-04-05 1981-07-07 Syva Company Kit for carrying out chemically induced fluorescence immunoassay
US4366241A (en) 1980-08-07 1982-12-28 Syva Company Concentrating zone method in heterogeneous immunoassays
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
EP0438310A1 (en) 1990-01-19 1991-07-24 Merck & Co. Inc. Method for producing recombinant immunoglobuline
US6018036A (en) 1990-06-29 2000-01-25 Schering Corporation Nucleic acids encoding cytokine synthesis inhibitory factor (Interleukin-10)
DE122004000008I1 (de) * 1991-06-14 2005-06-09 Genentech Inc Humanisierter Heregulin Antikörper.
EP0541214A3 (en) * 1991-08-06 1993-09-08 Schering Corporation Use of interleukin-10 analogs or antagonists to treat endotoxin- or superantigen induced toxicity
ATE297465T1 (de) 1991-11-25 2005-06-15 Enzon Inc Verfahren zur herstellung von multivalenten antigenbindenden proteinen
AU680628B2 (en) * 1992-08-20 1997-08-07 Schering Corporation Novel uses of IL-4 and/or IL-10, and antibodies against the same
DE19529026C2 (de) * 1995-07-28 1997-06-19 Robert Sabat Monoklonale Antikörper gegen humanes Interleukin-10
EP1261376A1 (en) * 2000-01-27 2002-12-04 Genetics Institute, LLC Antibodies against ctla4(cd152), conjugates comprising same, and uses thereof
PE20020574A1 (es) * 2000-12-06 2002-07-02 Wyeth Corp Anticuerpos humanizados que reconocen el peptido amiloideo beta
JP2005538706A (ja) * 2001-07-12 2005-12-22 ジェファーソン フーテ， スーパーヒト化抗体
WO2003032814A2 (en) * 2001-10-16 2003-04-24 Raven Biotechnologies, Inc. Antibodies that bind to cancer-associated antigen cd46 and methods of use thereof
CA2479927C (en) * 2002-03-29 2013-03-12 Schering Corporation Human monoclonal antibodies to interleukin-5 and methods and compositions comprising same

Also Published As

Publication number Publication date
AR074779A2 (es) 2011-02-09
CN1906213A (zh) 2007-01-31
HK1087722A1 (en) 2006-10-20
WO2005047326A2 (en) 2005-05-26
JP2008500020A (ja) 2008-01-10
JP4762148B2 (ja) 2011-08-31
US20140112919A1 (en) 2014-04-24
RS51180B (sr) 2010-10-31
AU2011200606A1 (en) 2011-03-03
CN100595212C (zh) 2010-03-24
EP2292661A3 (en) 2011-06-22
AU2004290044B2 (en) 2010-11-18
US8624013B2 (en) 2014-01-07
US7662379B2 (en) 2010-02-16
AR074780A2 (es) 2011-02-09
CA2545255C (en) 2013-06-25
US20120282253A1 (en) 2012-11-08
PE20050925A1 (es) 2005-11-29
KR20060120093A (ko) 2006-11-24
EP2128175A1 (en) 2009-12-02
AU2011200606B2 (en) 2012-05-10
US20050101770A1 (en) 2005-05-12
IL175523A (en) 2011-01-31
NO20062672L (no) 2006-06-09
JP2011087590A (ja) 2011-05-06
AU2004290044A1 (en) 2005-05-26
NZ546632A (en) 2009-07-31
CA2545255A1 (en) 2006-05-05
ZA200603681B (en) 2010-01-27
KR101175055B1 (ko) 2012-08-22
IL175523A0 (en) 2006-09-05
IL202681A0 (en) 2010-06-30
US20070178097A1 (en) 2007-08-02
JP2014014361A (ja) 2014-01-30
EP2123678A1 (en) 2009-11-25
IL202682A0 (en) 2010-06-30
KR20120025618A (ko) 2012-03-15
HRP20090517T1 (hr) 2009-10-31
KR20120023858A (ko) 2012-03-13
ATE440867T1 (de) 2009-09-15
US20100203049A1 (en) 2010-08-12
WO2005047324A2 (en) 2005-05-26
EP1694705A2 (en) 2006-08-30
JP2011062211A (ja) 2011-03-31
DK1694705T3 (da) 2009-12-07
SG155205A1 (en) 2009-09-30
ES2329907T3 (es) 2009-12-02
PT1694705E (pt) 2009-11-30
DE602004022855D1 (de) 2009-10-08
EP2292661A2 (en) 2011-03-09
IL202681A (en) 2011-10-31
US8226947B2 (en) 2012-07-24
WO2005047326A3 (en) 2005-12-22
CA2812856A1 (en) 2005-05-26
CN102010471A (zh) 2011-04-13
PE20090047A1 (es) 2009-01-26
PE20090046A1 (es) 2009-01-26
EP1694705B1 (en) 2009-08-26
CY1110557T1 (el) 2015-04-29
SI1694705T1 (sl) 2010-01-29
PL1694705T3 (pl) 2010-02-26

Similar Documents

Publication Publication Date Title
AR046833A1 (es) Anticuerpos anti-interleuquina-10
PE20110225A1 (es) Composiciones y metodos para anticuerpos que se dirigen a la proteina de complemento c5
IL273918B1 (en) Trispecific proteins and methods of use
RU2016106577A (ru) САЙТЫ АНТИТЕЛ, СПЕЦИФИЧНО СВЯЗЫВАЮЩИЕ EGFRvIII
SI2573121T1 (en) IL-4 and / or IL-13 binding antibodies and their uses
AR040046A1 (es) Anticuerpo neutralizante humano anti-igfr
PE20190976A1 (es) Anticuerpos de union a cd3
AR109355A2 (es) Moléculas de unión al receptor ox40 humano
ES2124224T3 (es) Metodo para escrutar genotecas recombinantes.
AR058322A1 (es) Proteinas de union especificas de factores de crecimiento tipo insulina y usos de las mismas
TW200745164A (en) Gene recombination antibodies composition
RU2010136940A (ru) Антитела против альфа5-бета1 и их применение
AR047372A1 (es) Anticuerpos contra madcam
BRPI0214137B8 (pt) anticorpo monoclonal humano ou porção de ligação a antígeno do mesmo que se liga especificamente ao cd40 humano e o ativa, linhagem celular de hibridoma isolado, composição farmacêutica compreendendo os mesmos, uso dos mesmos na fabricação de um medicamento e método de fabricação dos referidos anticorpos ou porção de ligação a antígeno do mesmo
AR077088A1 (es) Proteinas biespecificas de union a antigeno
RU2017144098A (ru) Гетеродимеризованный полипептид
AR035119A1 (es) Anticuerpos humanos antagonistas anti-htnfsf13b
RU2003129528A (ru) Способ экспрессии белков, содержащих в качестве компонента гибридный изотип антитела
PE20131334A1 (es) Anticuerpo igg1 humanizado
PE20220763A1 (es) Materiales y metodos para modular la inmunidad mediada por celulas t
AR085091A1 (es) Anticuerpos anti-kit y sus usos
EA200701363A1 (ru) Антитела против il-12, эпитопы, композиции, способы и применения
JP2019504617A5 (es)
PE20231080A1 (es) Anticuerpos que se unen a cd3 y cd19
AR124084A1 (es) ANTICUERPOS DE CADENA PESADA QUE SE UNEN AL RECEPTOR a DE FOLATO

Legal Events

Date Code Title Description
FG Grant, registration